First Eagle Investment Management
VIRX

First Eagle Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

First Eagle Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,414
Closed -$214K – 147
2019
Q2 		$214K Hold
8,414
– – ﹤0.01% 148
2019
Q1 		$358K Hold
8,414
– – ﹤0.01% 151
2018
Q4 		$122K Sell
8,414
-714
-8% -$29.1K ﹤0.01% 165
2018
Q3 		$639K Hold
9,128
– – ﹤0.01% 161
2018
Q2 		$677K Hold
9,128
– – ﹤0.01% 160
2018
Q1 		$869K Hold
9,128
– – ﹤0.01% 160
2017
Q4 		$1.18M Hold
9,128
– – ﹤0.01% 221
2017
Q3 		$620K Hold
9,128
– – ﹤0.01% 258
2017
Q2 		$863K Hold
9,128
– – ﹤0.01% 225
2017
Q1 		$1.31M Sell
9,128
-7,301
-44% -$1.04M ﹤0.01% 214
2016
Q4 		$2.08M Buy
16,429
+9,286
+130% +$1.29M 0.01% 199
2016
Q3 		$1.09M Hold
7,143
– – ﹤0.01% 239
2016
Q2 		$822K Buy
+7,143
New +$791K ﹤0.01% 256
2015
Q2 		– Sell
-2,800
Closed -$1.44M – 330
2015
Q1 		$1.44M Sell
2,800
-3,935
-58% -$1.99M ﹤0.01% 219
2014
Q4 		$3.61M Buy
+6,735
New +$3.03M 0.01% 190
2014
Q3 		– Sell
-952
Closed -$1.3M – 352
2014
Q2 		$1.3M Sell
952
-94
-9% -$109K ﹤0.01% 225
2014
Q1 		$1.45M Sell
1,046
-97
-8% -$113K ﹤0.01% 195
2013
Q4 		$1.14M Buy
1,143
+191
+20% +$197K ﹤0.01% 204
2013
Q3 		$992K Buy
+952
New +$1.02M ﹤0.01% 218

Other funds holding VIRX

ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

First Eagle Investment Management's VIRX Position: Q3 2019 in Review

First Eagle Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2019, closing a stake of 8,414 shares — an estimated $214K sold.

First Eagle Investment Management first reported a position in VIRX in Q3 2013 and held it in 19 quarters. The position peaked at $3.61M in Q4 2014. 49 funds tracked by Wall St. Rank hold VIRX as of Q3 2019.

  • First Eagle Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • First Eagle Investment Management sold 8,414 Viracta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $214K.
  • First Eagle Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 19 quarters.
  • First Eagle Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $3.61M in Q4 2014.
  • 49 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on First Eagle Investment Management's 13F filing for Q3 2019, filed 12 Nov 2019.